Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib versus danazol in symptomatic anemic myelofibrosis after prior JAK inhibitor therapy
2019-000583-18Phase 3Unknown
- Sponsor
- Sierra Oncology
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mivavotinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by Sierra Oncology. Primary endpoint: MFSAF total symptom score response rate at Week 24. Status: unknown.
02
Drugs
mivavotinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2019-000583-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000583-18.